Cellectar Biosciences Inc
CLRB4.980USD
+0.260+5.51%
Horário de mercado （ET）Cotações atrasadas em 15 min
7.65MValor de mercado
PerdaP/L TTM
Mais detalhes de Cellectar Biosciences Inc Empresa
Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The Company, through phospholipid ether drug conjugate (PDC) delivery platform, is focused on developing PDCs that are designed to specifically target cancer cells. Its PDC platform possesses the potential for the discovery and development of cancer-targeting treatments, and it plans to develop PDCs both independently and through research and development collaborations. Its product pipeline includes iopofosine, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), preclinical PDC chemotherapeutic programs and multiple partnered PDC assets. Its Iopofosine is evaluated in the completed CLOVER-WaM Phase 2 pivotal study in patients with relapsed/refractory (r/r) Waldenstrom’s macroglobulinemia (WM).
Informações da empresa
Código da empresaCLRB
Nome da EmpresaCellectar Biosciences Inc
Data de listagemMay 20, 2005
CEOMr. James V. Caruso
Número de funcionários11
Tipo de títulosOrdinary Share
Fim do ano fiscalMay 20
Endereço100 Campus Drive
CidadeFLORHAM PARK
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal07932
Telefone16084418120
Sitehttps://www.cellectar.com/
Código da empresaCLRB
Data de listagemMay 20, 2005
CEOMr. James V. Caruso
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Jarrod Longcor
Mr. Jarrod Longcor
Chief Operating Officer
Chief Operating Officer
12.77K
+360.88%
Mr. James V. Caruso
Mr. James V. Caruso
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
11.64K
+609.38%
Mr. Chad J. Kolean
Mr. Chad J. Kolean
Chief Financial Officer, Vice President, Secretary
Chief Financial Officer, Vice President, Secretary
6.42K
+352.36%
Mr. Douglas J. (Doug) Swirsky
Mr. Douglas J. (Doug) Swirsky
Independent Chairman of the Board
Independent Chairman of the Board
83.00
--
Mr. Stefan D. Loren, Ph.D.
Mr. Stefan D. Loren, Ph.D.
Independent Director
Independent Director
--
--
Mr. Frederick W. (Fred) Driscoll
Mr. Frederick W. (Fred) Driscoll
Independent Director
Independent Director
--
--
Mr. John P. Neis
Mr. John P. Neis
Independent Director
Independent Director
--
--
Dr. Asher Alban Chanan-Khan, M.D.
Dr. Asher Alban Chanan-Khan, M.D.
Independent Director
Independent Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Jarrod Longcor
Mr. Jarrod Longcor
Chief Operating Officer
Chief Operating Officer
12.77K
+360.88%
Mr. James V. Caruso
Mr. James V. Caruso
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
11.64K
+609.38%
Mr. Chad J. Kolean
Mr. Chad J. Kolean
Chief Financial Officer, Vice President, Secretary
Chief Financial Officer, Vice President, Secretary
6.42K
+352.36%
Mr. Douglas J. (Doug) Swirsky
Mr. Douglas J. (Doug) Swirsky
Independent Chairman of the Board
Independent Chairman of the Board
83.00
--
Mr. Stefan D. Loren, Ph.D.
Mr. Stefan D. Loren, Ph.D.
Independent Director
Independent Director
--
--
Mr. Frederick W. (Fred) Driscoll
Mr. Frederick W. (Fred) Driscoll
Independent Director
Independent Director
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sáb, 26 de jul
Atualizado em: sáb, 26 de jul
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
2.14%
UBS Financial Services, Inc.
1.11%
Adar1 Capital Management LLC
0.68%
Lytton (Laurence W)
0.63%
Geode Capital Management, L.L.C.
0.55%
Other
94.88%
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
2.14%
UBS Financial Services, Inc.
1.11%
Adar1 Capital Management LLC
0.68%
Lytton (Laurence W)
0.63%
Geode Capital Management, L.L.C.
0.55%
Other
94.88%
Tipos de investidores
Investidores
Proporção
Investment Advisor
3.70%
Individual Investor
1.91%
Investment Advisor/Hedge Fund
1.28%
Hedge Fund
1.21%
Corporation
0.36%
Research Firm
0.23%
Venture Capital
0.13%
Bank and Trust
0.03%
Other
91.15%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
84
202.41K
7.72%
-340.14K
2025Q1
86
199.12K
11.22%
-346.61K
2024Q4
85
5.89M
13.20%
-10.24M
2024Q3
82
15.21M
37.53%
+860.01K
2024Q2
87
12.77M
37.42%
+1.31M
2024Q1
84
10.31M
32.95%
-1.69M
2023Q4
71
9.17M
43.97%
+2.46M
2023Q3
74
3.14M
32.62%
+389.97K
2023Q2
83
3.71M
38.83%
+394.07K
2023Q1
91
3.81M
40.21%
+165.83K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
The Vanguard Group, Inc.
57.40K
2.14%
-172.00
-0.30%
Mar 31, 2025
UBS Financial Services, Inc.
29.84K
1.11%
+17.42K
+140.12%
Mar 31, 2025
Adar1 Capital Management LLC
18.19K
0.68%
+16.85K
+1256.45%
Apr 17, 2025
Lytton (Laurence W)
16.78K
0.63%
--
--
Apr 17, 2025
Geode Capital Management, L.L.C.
14.78K
0.55%
+3.08K
+26.38%
Mar 31, 2025
Longcor (Jarrod)
2.77K
0.18%
+1.00K
+56.47%
Apr 17, 2025
Squarepoint Capital LLP
12.36K
0.46%
-4.98K
-28.71%
Mar 31, 2025
Caruso (James V)
1.64K
0.11%
--
--
Apr 17, 2025
Citadel Advisors LLC
11.44K
0.43%
+11.44K
--
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
iShares Micro-Cap ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Micro-Cap ETF
Proporção0%
iShares Core S&P Total U.S. Stock Market ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Jul 21, 2022
Merger
10<1
Jul 21, 2022
Merger
10<1
Jul 21, 2022
Merger
10<1
Jul 21, 2022
Merger
10<1
Data
Tipo
Proporção
Jul 21, 2022
Merger
10<1
Jul 21, 2022
Merger
10<1
Jul 21, 2022
Merger
10<1
Jul 21, 2022
Merger
10<1
